# **17-AAG**

#### **HSP90** inhibitor

17-AAG is a less toxic and more stable analog of geldanamycin. It is an HSP90 inhibitor that displays a 100-fold higher affinity for HSP90 derived from tumor cells compared to HSP90 from normal cells. 17-AAG inhibits Akt activation and expression in tumors and synergizes with a number of antitumor agents such as taxol, cisplatin, and UCN-014. 17-AAG causes the inactivation, destabilization and eventual degradation of HIF-1 $\alpha$ . Inhibitor of telomerase activity. Inducer of apoptosis with antitumor activity. Inducer of macroautophagy.

Citations: 37

View Online »


**Ordering Information** 

**Order Online** »

**BML-EI308-0001** 1mg

Manuals, SDS & CofA

View Online »



## **Handling & Storage**

**Use/Stability** As indicated on product label or CoA when stored as recommended.

**Handling** Protect from light.

Long Term Storage -20°C

**Shipping** Ambient Temperature

# Regulatory Status RUO - Research Use Only

### **Product Details**

Alternative Name 17-(Allylamino)-17-desmethoxygeldanamycin

**Appearance** Red to dark red or purple solid.

CAS 75747-14-7

Couple Target HSP90

Couple Type Inhibitor

Formula  $C_{31}H_{43}N_3O_8$ 

**Identity** Determined by 1H-NMR.

**MW** 585.7

**Purity** ≥98% (TLC)

**Solubility** Soluble in DMSO (>20mg/ml) or 100% ethanol (10mg/ml).

**Source** Semisynthetic derivative from geldanamycin.

Technical Info / Product Notes Replacement for ADI-HPK-101.

